PharmaDrug Inc CEO Daniel Cohen tells Proactive it has appointed Dr Cindy Hutnik to the company’s scientific and clinical advisory board.
Cohen says Hutnik will assist the company in its ongoing efforts to develop DMT and other related tryptamine analogues as a potential treatment for glaucoma.